Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931708 | 1.00 | HSD17B10 (0.56) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL25623600 | 1.00 | HSD17B10 (0.56) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL26728273 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL26728250 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL14179806 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL26728265 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL13257581 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL14071038 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL26803177 | 0.98 | HSD17B10 (0.55) | HSD17B10KMT2ATARDBPALDH1A1CYP2C9 | |
| SCHEMBL13784211 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134266-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4282411-A1 | LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATIVE DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY | Ischemix LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2020212755-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212760-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
| CN-109925279-A | A kind of lipoic acid injection and preparation method thereof | 大连中信药业股份有限公司 | 2019-06-25 | — | — | CN | disclosed |
| WO-2018053706-A1 | COMPOSITION COMPRISING PAEONIFLORIN OR ALBIFLORIN ANALOGUE, METHOD OF PREPARATION THEREOF | L'OREAL (FR) | 2018-03-29 | — | — | WO | disclosed |
| US-20120027781-A1 | Neuroprotective and neurorestorative method and compositions | SHASHOUA VICTOR E (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20100247587-A1 | PIGMENTATION-REGULATING COMPOUNDS | LIPOTEC, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| WO-2010045575-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS | INVASC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-06-26 | — | — | US | disclosed |
| US-7378438-B2 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-05-27 | — | — | US | disclosed |
| US-7320867-B2 | Linker compound, ligand, and producing method thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-01-22 | — | — | US | disclosed |
| WO-2001060988-A2 | BIOTECHNOLOGICALLY INTERESTING PROTEINS FROM CAT SHARKS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027781-A1 | Neuroprotective and neurorestorative method and compositions | BDNF, NLN, NEFM | HSD17B10 3547/4885KMT2A 3895/4885TARDBP 57/4885 |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | CBS, PSEN1, PSEN2 | HSD17B10 1875/4885KMT2A 3172/4885TARDBP 1808/4885 |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | ADRA2B, ADRA1B, ADRB1 | HSD17B10 937/4885KMT2A 4576/4885TARDBP 3074/4885 |
| US-20100247587-A1 | PIGMENTATION-REGULATING COMPOUNDS | TYR, MC1R, MITF | HSD17B10 858/4885KMT2A 1187/4885TARDBP 4783/4885 |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | HSD17B10 292/4885KMT2A 3405/4885TARDBP 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.